[1]韦永刚,付德安.噻托溴铵吸入剂与沙美特罗替卡松粉吸入剂联合治疗对中重度慢性阻塞性肺疾病稳定期患者肺功能和生活质量的影响[J].新乡医学院学报,2018,35(8):739-742.[doi:10.7683/xxyxyxb.2018.08.023]
 WEI Yong-gang,FU De-an.Effects of tiotropium bromide inhalation and salmeterol xinafoate and fluticasone propionate powder for inhalation on lung function and quality of life in patients with moderate and severe chronic obstructive pulmonary disease in stable stage[J].Journal of Xinxiang Medical University,2018,35(8):739-742.[doi:10.7683/xxyxyxb.2018.08.023]
点击复制

噻托溴铵吸入剂与沙美特罗替卡松粉吸入剂联合治疗对中重度慢性阻塞性肺疾病稳定期患者肺功能和生活质量的影响
分享到:

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
35
期数:
2018年8
页码:
739-742
栏目:
临床研究
出版日期:
2018-08-05

文章信息/Info

Title:
Effects of tiotropium bromide inhalation and salmeterol xinafoate and fluticasone propionate powder for inhalation on lung function and quality of life in patients with moderate and severe chronic obstructive pulmonary disease in stable stage
作者:
韦永刚1付德安2
(1.重庆市开州区人民医院呼吸内科,重庆 405400;2.重庆市开州区人民医院神经内科,重庆 405400)
Author(s):
WEI Yong-gang1FU De-an2
(1.Department of Respiratory Medicine,the People′s Hospital of Kaizhou District of Chongqing City,Chongqing 405400,China;2.Department of Neurology,the People′s Hospital of Kaizhou District of Chongqing City,Chongqing 405400,China)
关键词:
慢性阻塞性肺疾病沙美特罗替卡松粉噻托溴铵吸入剂肺功能生活质量
Keywords:
chronic obstructive pulmonary diseasesalmeterol xinafoate and fluticasone propionate powdertiotropium bromidelung functionquality of life
分类号:
R563
DOI:
10.7683/xxyxyxb.2018.08.023
文献标志码:
A
摘要:
目的 探讨噻托溴铵吸入剂联合沙美特罗替卡松粉吸入剂治疗中重度慢性阻塞性肺疾病(COPD)稳定期患者的临床效果。方法 选择2014年12月至2016年12月重庆市开州区人民医院收治的78例中重度COPD稳定期患者为研究对象,根据治疗方法将患者分为观察组和对照组,每组39例。2组患者入院后均给予吸氧、抗感染、止咳、平喘、化痰、营养支持等常规治疗,在常规治疗基础上,对照组患者给予沙美特罗替卡松粉吸入剂治疗,观察组患者给予噻托溴铵吸入剂联合沙美特罗替卡松粉吸入剂治疗;比较2组患者治疗前后肺功能、呼吸困难评分、6 min步行距离、圣·乔治医院呼吸问题调查问卷(SGRQ)评分及不良反应发生率。结果 治疗前2组患者第1秒用力呼气量(FEV1)、用力肺活量(FVC)、FEV1/FVC比较差异均无统计学意义(P>0.05),2组患者治疗后FEV1、FVC、FEV1/FVC显著高于治疗前(P<0.05),治疗后观察组患者FEV1、FVC、FEV1/FVC显著高于对照组(P<0.05)。治疗前2组患者呼吸困难评分及6 min步行距离比较差异均无统计学意义(P>0.05);2组患者治疗后呼吸困难评分显著低于治疗前(P<0.05),6 min步行距离显著大于治疗前(P<0.05);治疗后,观察组患者呼吸困难评分显著低于对照组(P<0.05),6 min步行距离显著大于对照组(P<0.05)。SGRQ评分显示,治疗前2组患者疾病影响、呼吸症状、活动能力评分及总评分比较差异均无统计学意义(P>0.05),2组患者治疗后疾病影响、呼吸症状、活动能力评分及总评分显著低于治疗前 (P<0.05);治疗后,观察组患者疾病影响、呼吸症状、活动能力评分及总评分显著低于对照组(P<0.05)。观察组和对照组患者不良反应发生率分别为15.38%(6/39)、10.26%(4/39),2组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论 噻托溴铵吸入剂与沙美特罗替卡松粉吸入剂联合治疗可以显著改善COPD稳定期患者肺功能及生活质量。
Abstract:
Objective To investigate the effect of tiotropium bromide inhalation combined with salmeterol xinafoate and fluticasone propionate powder for inhalation in the treatment of patients with moderate and severe chronic obstructive pulmonary disease(COPD) in stable stage.Methods A total of 78 patients with moderate and severe COPD in stable stage in the People′s Hospital of Kaizhou District of Chongqing City from December 2014 to December 2016 were selected as the subjects.The patients were divided into observation group and control group according to the treatment method,39 cases in each group.The patients in the two groups were given routine treatment such as oxygen inhalation,anti-infection,cough relieving,antiasthma,dissipate phlegm,nutritional support and so on.On the basis of routine treatment,the patients in the control group were treated with salmeterol xinafoate and fluticasone propionate powder for inhalation,and the patients in the observation group were treated with tiotropium bromide inhalation combined with salmeterol xinafoate and fluticasone propionate powder for inhalation.The lung function,dyspnea score,6 min walking distance,St.George′s Respiratory Questionnaire (SGRQ) score and the incidence of adverse reactions were compared between the two groups before and after treatment.Results There was no significant difference in forced expiratory volume in one second (FEV1),forced vital capacity (FVC) and FEV1/FVC between the two groups before treatment (P>0.05).The FEV1,FVC and FEV1/FVC after treatment were significantly higher than those before treatment in the two groups (P<0.05).The FEV1,FVC and FEV1/FVC in the observation group were significantly higher than those in the control group after treatment (P<0.05).There was no significant difference in the dyspnea score and 6 minutes walking distance between the two groups before treatment (P>0.05).The dyspnea score after treatment were significantly lower than that before treatment (P<0.05),and the 6 minutes walking distance after treatment was significantly higher than that before treatment in the two groups (P<0.05).The dyspnea score in the observation group was significantly lower than that in the control group after treatment (P<0.05),and the 6 minutes walking distance in the observation group was significantly higher than that in the control group (P<0.05).SGRQ score showed that there was no significant difference in the scores of disease effects,respiratory symptoms,activity ability and total score between the two groups before treatment (P>0.05);the scores of disease effects,respiratory symptoms,activity ability and total score after treatment were significantly lower than those before treatment in the two groups(P<0.05);the scores of disease effects,respiratory symptoms,activity ability and total score in the observation group were significantly lower than those in the control group after treatment (P<0.05).The incidence of adverse reactions in the observation group and the control group was 15.38% (6/39) and 10.26% (4/39) respectively,there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Tiotropium bromide inhalation combined with salmeterol xinafoate and fluticasone propionate powder for inhalation can significantly improve lung function and quality of life in patients with COPD in stable stage.

参考文献/References:

[1] 徐海林,董竞成.慢性阻塞性肺疾病诊疗进展[J].医学综述,2013,19(6):970-972.
[2] 王运.布地奈德联合福莫特罗雾化吸入治疗慢性阻塞性肺疾病的效果及其对患者肺功能和炎性递质的影响[J].新乡医学院学报,2017,34(10):932-935.
[3] 许迎辉,李响,韩玉英.噻托溴铵联合沙美特罗/丙酸氟替卡松吸入治疗对慢性阻塞性肺疾病患者肺功能的影响[J].中国医药导报,2016,13(3):146-149.
[4] SEKINE Y,FUJISAWA T,SUZUKI K,et al.Detection of chronic obstructive pulmonary disease in community-based annual lung cancer screening:Chiba Chronic Obstructive Pulmonary Disease Lung Cancer Screening Study Group[J].Respirology,2014,19(1):98-104.
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南:2013年修订版[J].中华结核和呼吸杂志,2013,36(4):255-264.
[6] VIGLIO S,STOLK J,LUISETTI M,et al.From micellar electrokinetic chromatography to liquid chromatography-mass spectrometry:revisiting the way of analyzing human fluids for the search of desmosines,putative biomarkers of chronic obstructive pulmonary disease[J].Electrophoresis,2014,35(1):109-118.
[7] 庞才双,曾妮,申永春,等.慢性阻塞性肺疾病气道重塑机制及其研究进展[J].西部医学,2017,29(1):135-140.
[8] 罗志成,吴国振,袁星.慢性阻塞性肺疾病治疗药物研究进展[J].药学实践杂志,2017,35(3):201-204,242.
[9] 欧莉梅,钟小宁.慢性阻塞性肺疾病稳定期抗炎治疗相关进展[J].中华内科杂志,2009,48(5):421-424.
[10] CALZETTA L,ROGLIANI P,MATERA M G,et al.A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD[J].Chest,2016,149(5):1181-1196.
[11] 常春,姚婉贞.噻托溴铵治疗慢性阻塞性肺疾病十年回顾与展望[J].中华结核和呼吸杂志,2016,39(3):217-220.
[12] 车向前,马菲菲,张云,等.噻托溴铵治疗尘肺伴慢性阻塞性肺疾病对肺功能和血气指标的影响[J].疑难病杂志,2016,15(6):579,583.
[13] 张雨萌.沙美特罗氟替卡松在慢性阻塞性肺疾病中的应用[J].热带医学杂志,2017,17(1):56-58.
[14] VIVIERS P J,VAN ZYL-SMIT R N.Chronic obstructive pulmonary disease:diagnosis and classification of severity[J].S Afr Med J,2015,105(9):786-788.
[15] 李锐,刘新,卢来春,等.沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病急性加重期疗效和安全性的Meta分析[J].中国药房,2015,26(21):2950,2953.

相似文献/References:

[1]史册.慢性阻塞性肺疾病急性发作期的营养支持治疗[J].新乡医学院学报,2001,18(06):444.
[2]袁晓梅,孙 云,袁宇.慢性阻塞性肺疾病肺心病患者血浆内皮素测定的临床价值[J].新乡医学院学报,2002,19(04):273.
[3]郭志强.慢性阻塞性肺疾病60例院内获得性真菌感染与耐药性分析 [J].新乡医学院学报,2006,23(02):000.
[4]程思远.慢性阻塞性肺疾病继发真菌感染65例病原菌分布及耐药性分析[J].新乡医学院学报,2009,26(01):073.
[5]杨华,周志才,奚峰,等.无创正压通气治疗慢性阻塞性肺疾病急性加重期伴Ⅱ型呼吸衰竭[J].新乡医学院学报,2011,28(02):216.
[6]殷波,惠复新,赵寅滢,等.慢性阻塞性肺疾病急性加重期三重酸碱失衡与急性生理学和慢性健康状况评分Ⅲ评分及预后的关系 [J].新乡医学院学报,2011,28(03):346.
[7]刘金花,徐吟亚,付波.低分子肝素钙对慢性阻塞性肺疾病急性加重期患者血栓前状态的影响[J].新乡医学院学报,2012,29(09):680.
[8]王 沁,郭建辉,梁 栋,等.健脾益肺口服液对慢性阻塞性肺疾病“肺脾气虚证”大鼠动脉血气的影响[J].新乡医学院学报,2014,31(11):896.[doi:10.7683/xxyxyxb.2014.11.00]
[9]朱木林1,袁云华1,邓 巍2,等.慢性阻塞性肺疾病合并外周骨骼肌功能障碍患者炎性因子和代谢水平及线粒体功能的变化[J].新乡医学院学报,2015,32(05):412.
[10]李 航,郭伟丽,安 珍,等.PM2.5对慢性阻塞性肺疾病影响研究进展[J].新乡医学院学报,2016,33(3):234.[doi:10.7683/xxyxyxb.2016.03.020]
 LI Hang,GUO Weili,AN Zhen,et al.Research progress on the effect of PM2.5 on chronic obstructive pulmonary disease[J].Journal of Xinxiang Medical University,2016,33(8):234.[doi:10.7683/xxyxyxb.2016.03.020]

更新日期/Last Update: 2018-08-05